The US Food and Drug Administration has approved privately-held US biotech firm Protein Sciences’ strain change amendment for its seasonal influenza vaccine, Flublok (trivalent recombinant hemagglutinin vaccine).

Every year influenza vaccine manufacturers must receive approval from the Agency for changes they make to the upcoming season's manufacturing process and product formulation, as the influenza vaccine is adapted annually. Early approval for Flublok will enable delivery on time to health care providers in the fall. This is especially important for those that rely on Flublok's unique properties for protection from the flu; namely, that the vaccine is egg-free, highly pure and triple the strength compared to conventional influenza vaccines.

Flublok vaccines available in September